Drugs / Hypromellose
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05470868 | Feb → May 2023 | ocular hyperemia | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00909324 | Aug 2009 → Jan 2010 | dry eye syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00598689 | Oct 2007 → Oct 2009 | corneal disorder | Augusta University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06089317 | Jul 2024 → Jun 2025 | dry eye syndrome | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT04970329 | Jul 2021 | dry eye syndrome | University of Faisalabad | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT03676335 Background | May 2018 → Jun 2019 | dry eye syndrome | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT06373653 Comparator | Feb 2025 | asthenopia | Laboratorios Sophia S.A de C.V. | Withdrawn | No outcome recorded |
| Phase 4 | NCT02097719 Comparator | May → Dec 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01881126 Comparator | Jun 2013 → Oct 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01170884 Comparator | Dec 2009 → Sep 2010 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| — | NCT05577910 Background | Oct 2022 → Dec 2024 | eye adnexa disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT06358456 Comparator | Nov 2020 → Apr 2022 | — | University Clinic Frankfurt | Completed | No outcome recorded |
| — | NCT01812044 Background | Mar 2013 → Dec 2014 | strabismus | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hypromellose | “The active ingredient is hypromellose (1.92 mg per 0.6 ml container).” NCT06358456 ↗12“lubricant eye drop (Hypromellose 0.3% w/v Eye Drops)” NCT06089317 ↗ “Hypromellose 0.5%, Ophthalmic solution.” NCT06373653 ↗ |
| Route | Topical | “applied topically” NCT01812044 ↗ |